(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(2-oxopiperidin-1-yl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one | 1402796-96-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(2-oxopiperidin-1-yl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
• 英文别名: (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-[[2-[2-methoxy-5-(2-oxopiperidin-1-yl)phenyl]-5,5-dimethylcyclohexen-1-yl]methyl]-4-methyl-1,3-oxazolidin-2-one
• CAS: 1402796-96-6
• 化学式: C₃₃H₃₆F₆N₂O₄
• 分子量: 638.65
• InChiKey: WLAAGMZYBBYJQL-SLQAJWMNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.8
• 重原子数：
  45
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  59.1
• 氢给体数：
  0
• 氢受体数：
  10

文献信息

• CYCLOALKENYL ARYL DERIVATIVES FOR CETP INHIBITOR
  申请人：Lee SeoHee

  公开号：US20140031335A1

  公开（公告）日：2014-01-30

  The present invention relates to cycloalkenyl aryl derivatives, isomers thereof, pharmaceutically acceptable salts thereof, hydrates thereof, or solvates thereof; a method for preparing the derivatives; and pharmaceutical compositions containing the same. The compounds of the present invention show the effect of CETP activity inhibition. It means that the compounds can increase HDL-cholesterol and decrease LDL-cholesterol.

  本发明涉及环烯基芳基衍生物及其异构体、药学上可接受的盐、水合物或溶剂合物；制备这些衍生物的方法；以及含有这些衍生物的药物组合物。本发明的化合物显示出CETP活性抑制的效果。这意味着这些化合物可以增加HDL-胆固醇并降低LDL-胆固醇。
• 3-(2-ARYL-CYCLOALKENYLMETHYL)-OXAZOLIDIN-2-ONE DERIVATIVES AS CHOLESTEROL ESTER TRANSFER PROTEIN (CETP) INHIBITORS
  申请人：Chong Kun Dang Pharmaceutical Corp.

  公开号：EP2697207B1

  公开（公告）日：2016-12-14
• US9371294B2
  申请人：——

  公开号：US9371294B2

  公开（公告）日：2016-06-21
• [EN] CYCLOALKENYL ARYL DERIVATIVES FOR CETP INHIBITOR<br/>[FR] DÉRIVÉS CYCLOALCÉNYL ARYLE POUR UN INHIBITEUR DE LA PROTÉINE DE TRANSFERT DU CHOLESTÉROL ESTÉRIFIÉ (CETP)
  申请人：CHONG KUN DANG PHARM CORP

  公开号：WO2012141487A2

  公开（公告）日：2012-10-18

  The present invention relates to cycloalkenyl aryl derivatives, isomers thereof, pharmaceutically acceptable salts thereof, hydrates thereof, or solvates thereof; a method for preparing the derivatives; and pharmaceutical compositions containing the same. The compounds of the present invention show the effect of CETP activity inhibition. It means that the compounds can increase HDL-cholesterol and decrease LDL-cholesterol.